Abliva
0.245 SEK -5.96%Be the first to follow this company
Abliva is a pharmaceutical company. The company develops drugs for the treatment of primary mitochondrial diseases. These congenital, rare and often very serious diseases occur when the cell's energy supply, the mitochondria, does not function properly. The portfolio includes projects in various stages and ranges from the early detection phase to the clinical phase. The company was previously known as NeuroVive Pharmaceutical.
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
ABLI
Daily low / high price
0.242 / 0.26
SEK
Market cap
394.11M SEK
Turnover
1.32M SEK
Volume
5.3M
Financial calendar
Interim report
22.08.2024
Interim report
21.11.2024
Annual report
21.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Hadean Capital I AS | 22.4 % | 22.4 % |
Oslo Pensjonsforsikring AS | 14.9 % | 14.9 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Positive interim analysis in Abliva's FALCON study triggers convertible loan conversion
Abliva Announces Positive Interim Analysis of the FALCON Study for KL1333 in Primary Mitochondrial Disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools